Anti-angiogenic therapy targeting VEGF, CD276, or endothelin B receptor has been shown to normalize tumor vasculature and could be used in combination with targeted therapy like CAR T cells to increase tumor infiltration (97, 98). Here, CD276 is linked to neoplasm.